MoonLake Immunotherapeutics
$ 49.67
-2.34%
15 Jul - close price
- Market Cap 3,228,303,000 USD
- Current Price $ 49.67
- High / Low $ 51.45 / 49.32
- Stock P/E N/A
- Book Value 6.42
- EPS -2.30
- Next Earning Report 2025-08-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.31 %
- 52 Week High 58.26
- 52 Week Low 31.42
About
None
Analyst Target Price
$78.31
Quarterly Earnings
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-05-05 | 2025-02-26 | 2024-11-12 | 2024-08-07 | 2024-05-07 | 2024-02-29 | 2023-11-14 | 2023-08-10 | 2023-05-12 | 2023-03-20 | 2022-11-14 | 2022-08-12 |
| Reported EPS | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 | -0.12 | -0.18 | -0.23 | -0.23 | -0.31 | -0.27 | -0.34 |
| Estimated EPS | -0.7355 | -0.5928 | -0.44 | -0.28 | -0.19 | -0.23 | -0.23 | -0.27 | -0.31 | -0.33 | -0.32 | -0.54 |
| Surprise | 0.1055 | -0.1272 | -0.12 | -0.11 | -0.03 | 0.11 | 0.05 | 0.04 | 0.08 | 0.02 | 0.05 | 0.2 |
| Surprise Percentage | 14.344% | -21.4575% | -27.2727% | -39.2857% | -15.7895% | 47.8261% | 21.7391% | 14.8148% | 25.8065% | 6.0606% | 15.625% | 37.037% |
Next Quarterly Earnings
| Jun 2025 | Sep 2025 | |
|---|---|---|
| Reported Date | 2025-08-07 | 2025-11-18 |
| Fiscal Date Ending | 2025-06-30 | 2025-09-30 |
| Estimated EPS | -0.7206 | -0.7435 |
| Currency | USD | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLTX
2025-06-13 18:08:45
Keytruda reduced the risk of recurrence, progression, or death by 30% vs. standard of care in HNSCC patients. Median event-free survival was 59.7 months with Keytruda vs. 29.6 months with standard care. Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 Days - Get The Details Now
2025-06-06 19:37:15
PatientPoint, Infucare and Moonlake Immunotherapeutics are up for sale. Alex Jones may see his personal assets - including guns, cars, and homes - sold by the end of the year. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
2025-06-04 16:06:00
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
2025-06-03 15:02:47
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Tuesday. Shares of Signet Jewelers Limited SIG rose sharply during Tuesday's session after the company reported better-than-expected first-quarter financial results and raised its FY26 guidance.
2025-06-03 11:38:09
Merck made a nonbinding offer of over $3 billion for MoonLake, whose lead drug is in Phase 3 trials for arthritis and skin disorders. Investor pressure is rising on Merck as Keytruda nears patent expiration, Gardasil sales fall in China, and Winrevair growth underperforms.
2025-06-03 10:30:29
Shares of Credo Technology Group Holding Ltd CRDO rose sharply in today's pre-market trading following upbeat quarterly results. The company reported fourth-quarter revenue of $170.03 million, beating analyst estimates of $162.96 million.
